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ntwerp, Genk, and Leuven, Belgium; Southampton, United Kingdom;
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bjectives The aim of this study was to compare, in a randomized multicenter trial, paclitaxel-elut-
ng stents (CoStar, Conor Medsystems, Menlo Park, California) versus pimecrolimus-eluting stents
Corio, Conor Medsystems) versus stents with dual elution of both drugs (SymBio, Conor Medsys-
ems) in native coronary arteries.
ackground The CoStar cobalt-chromium reservoir-based stent platform, eluting paclitaxel in a con-
rolled way via a bioresorbable polymer, reduces restenosis versus its respective bare-metal stent.
he reservoir system allows the use of other drugs targeted to different mechanisms involved in the
rocess of vascular restenosis and simultaneous loading of multiple, synergistic drugs.
ethods Patients with single de novo lesions were asymmetrically randomized to 1 of the 3 types of
tent (1:2:2). Six-month coronary angiography was planned in all. The primary analysis was a noninferior-
ty test for the primary end point of 6-month angiographic in-stent late lumen loss of Corio versus
oStar and SymBio versus CoStar. Secondary end points included binary angiographic restenosis and
ajor adverse clinical events (cardiac death, myocardial infarction, target vessel revascularization).
esults The trial was prematurely suspended after 246 patients were enrolled (planned enrollment: 375
atients): 49 patients received CoStar, 97 received SymBio, and 100 received Corio. In-stent late loss was
igniﬁcantly reduced with CoStar versus either SymBio or Corio (0.58  0.58 mm vs. 0.96  0.73 mm
nd 0.58  0.58 mm vs. 1.40  0.67 mm, p  0.001 for both comparisons). Binary in-stent restenosis
ates were, 7.1%, 20%, and 40.9%, respectively (p  0.001 for both comparisons); 6-month major adverse
ardiac event rates were, 2.0%, 14.4%, and 39.0%, respectively (p  0.001 for both comparisons).
onclusions Stents eluting pimecrolimus or the dual combination of pimecrolimus and paclitaxel
ailed to show angiographic noninferiority when compared with paclitaxel-eluting stents. (A Ran-
omized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coro-
ary Stent Systems; NCT00322569) (J Am Coll Cardiol Intv 2009;2:205–14) © 2009 by the American
ollege of Cardiology Foundationrom the *Antwerp Cardiovascular Institute Middelheim, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium; †Southampton
niversity Hospital, Southampton, United Kingdom; ‡Oost-Limburg Hospital, Genk, Belgium; §Charité Medical School,
T
f
e
d
l
r
a
t
k
h
c
r
i
e
o
C
a
c
s
(
t
m
U
M
d
s
i
e
f
i
t
n
r
n
m
r
i
t
s
p
s
n
r
a
M
T
p
s
n
m
t
i
P

a
i
t
a
p
7
t
(
p
m
m
H
¶
G
v
r
C
R
M
D
p
A
f
2
A
a
I
u
M
c
M
M
d
Q
a
P
s
R
d
T
r
T
r
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 3 , 2 0 0 9
M A R C H 2 0 0 9 : 2 0 5 – 1 4
Verheye et al.
The GENESIS Trial
206he CoStar stent (Conor Medsystems, Menlo Park, Cali-
ornia) is a cobalt chromium alloy stent platform designed to
lute paclitaxel without the use of a surface polymer and
rug coating but with a technology consisting of multiple
aser-cut reservoirs within the stent struts (Fig. 1). These
eservoirs are filled with a polymer/drug matrix consisting of
bioresorbable poly-lactic-co-glycolic polymer and pacli-
axel. The drug elution occurs with both directional and
inetic control. The CoStar paclitaxel-eluting stent (PES)
as been proven superior to the respective bare cobalt
hromium stent in reducing angiographic restenosis and
epeated revascularizations at 8 months (1).
Whereas the CoStar PES failed to demonstrate non-
nferiority to the first-generation Taxus PES (Boston Sci-
ntific, Maple Grove, Minnesota) for the primary end point
f 8-month major adverse cardiac events (MACE) in the
OSTAR (Cobalt Chromium Stent with Antiprolif-
erative for Restenosis) II trial
(2), the concept of reservoir
technology of the stent, associ-
ated with the bioresorbable
polymer delivery matrix, still
offers the potential for alterna-
tive dose kinetic and elution
profile improvements aimed at
developing more effective and
safer drug-eluting stents. In-
deed, this technology allows
loading and independent elu-
tion control of drugs targeting
various mechanisms involved
in the restenotic process. It also
permits simultaneous indepen-
dent delivery from a single
stent of more than 1 therapeu-
tic agent by placing different
polymer/drug combinations in
lternate, adjacent reservoirs. This combined delivery can
oncurrently address multiple physiologic stimuli respon-
ible for the pathological events after stent implantation
3). Once the discharge of the loaded drug(s) is complete,
he polymeric delivery matrix is absorbed, leaving a bare
etal stent implanted.
Pimecrolimus is a compound, currently approved by the
.S. Food and Drug Administration and the European
edicines Agency for the topical treatment of atopic
umboldt-Universität, Berlin, Germany; Rangueil Hospital, Toulouse, France;
Medical Care Center, Hamburg University Cardiovascular Center, Hamburg,
ermany; #Hadassah-Hebrew University Medical Centre, Jerusalem, Israel; **Uni-
ersity Hospital Gasthuisberg, Leuven, Belgium; ††Clinical Research Cordis Corpo-
ation, Warren, New Jersey; ‡‡Stanford University Medical Center, Stanford,
alifornia; and the §§Columbia University Medical Center and Cardiovascular
bbreviations
nd Acronyms
VUS  intravascular
ltrasound
ACE  major adverse
ardiac event
I  myocardial infarction
LD  minimal luminal
iameter
CA  quantitative coronary
ngiography
ES  paclitaxel-eluting
tent(s)
VD  reference vessel
iameter
LR  target lesion
evascularization
VR  target vessel
evascularizationesearch Foundation, New York, New York. This work received funding from Conor Mermatitis. It is an anti-inflammatory agent with immuno-
uppressant properties, belonging to the class of calcineurin-
nhibitors. Pimecrolimus inhibits the activation and prolif-
ration of T-lymphocytes and the release of several growth
actors. In addition, it targets mast cell release of pro-
nflammatory mediators including histamine, cytokines,
ryptase, and eicosanoids (4). Even though this agent does
ot exert any specific antiproliferative action, it might
educe the response of smooth muscle cell proliferation and
eointimal hyperplasia by decreasing the localized inflam-
atory response and the resultant cascade of physiologic
eactions secondary to the arterial injury caused by stent
mplantation (5,6).
This study was designed to determine the effectiveness of
he anti-inflammatory molecule pimecrolimus alone and the
ynergistic combination of pimecrolimus with an anti-
roliferative agent such as paclitaxel (with the potential of
imultaneous inhibition of 2 different mechanisms of reste-
osis), loaded in a drug-eluting stent with the Conor
eservoir technology, on the neointimal reaction process
ssessed in humans by angiography.
ethods
he GENESIS (randomized, multicenter study of the
imecrolimus-eluting and paclitaxel-elutinG coronary
tent system in patiENts with de novo lEsionS of the
ative coronary arterIeS) trial is a prospective, asym-
etrically randomized, multicenter, open-label, 3-arm
rial. The local ethics committee of every hospital enroll-
ng patients approved the trial design.
atient population. Patients were included if they were
18 years of age, with documented stable or unstable
ngina pectoris and had 1 de novo target lesion 25 mm
n length, with a reference vessel diameter (RVD) of 2.5
o 3.5 mm and with visually estimated stenosis of 50%
nd 100%, localized in a native coronary artery.
Clinical exclusion criteria were: woman of childbearing
otential; myocardial infarction (MI) within the previous
2 h; cardiogenic shock; documented left ventricular ejec-
ion fraction 25%; acute or chronic renal dysfunction
creatinine2.0 mg/dl); cerebrovascular accident within the
ast 6 months; gastrointestinal bleeding within the past 3
onths; thrombocytopenia (platelet count 100,000/
m3); contraindications to aspirin, clopidogrel, or contrast
edsystems. Dr. Dawkins is currently an employee of Boston Scientific Corporation.
r. Cohen is an employee of Cordis-Johnson & Johnson. The results of this trial were
resented at the 2008 Society for Cardiovascular Angiography and Interventions/
merican College of Cardiology Innovations in Interventions (SCAI/ACCi2) Con-
erence Proceedings (Late Breaking Clinical Trial session), held in Chicago (March
9 to April 1, 2008).anuscript received December 15, 2008; accepted December 21, 2008.
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207gents; known sensitivity to pimecrolimus, paclitaxel, cobalt
hromium, or the poly-lactic-co-glycolic polymer; current
ssumption of colchicine; chronic systemic steroid or im-
unosuppressant therapy or systemic paclitaxel assumption
ithin 12 months of the index procedure; life expectancy
24 months; or current participation in another investiga-
ional drug or device study. Angiographic exclusion criteria
ere: prior revascularization of the target vessel within the
receding 6 months, left main stenosis, ostial stenosis,
ifurcation lesion, severe calcification or the presence of
hrombus by visual estimation, pretreatment of the target
esion with any unapproved device or atherectomy or laser or
utting balloon, or prior brachytherapy in the target vessel.
ll enrolled patients provided written informed consent
efore the index procedure.
rocedural protocol, randomization, and follow-up. After
ercutaneous access was obtained, heparin was adminis-
ered to maintain an activated clotting time 250 s (or
200 s if glycoprotein IIb/IIIa inhibitors were given).
lycoprotein IIb/IIIa inhibitors were given at the oper-
tor’s discretion. Randomization was performed after
aseline angiography was obtained, with a computerized
entral randomization service. Randomization was strat-
fied by site and was accomplished at each site with an
nteractive voice randomization system. Eligible patients
ere randomized in a ratio of 1:2:2, respectively, to 1 of
Figure 1. The CoStar Stent
Photograph of the CoStar stent (A). Magniﬁcation demonstrates the laser-cut rtreatment arms: CoStar PES (11-g nominal dose in a r.0  16 mm stent) or SymBio (Conor Medsystems)
imecrolimus/paclitaxel-eluting stent (162.5-g pimecroli-
us/11-g paclitaxel nominal dose in a 3.0 16 mm stent) or
orio (Conor Medsystems) pimecrolimus-eluting stent
325-g nominal dose in a 3.0  16 mm stent). Direct
tenting was allowed and left at operator’s discretion. In
ase of dissection or incomplete lesion coverage, the use
f additional stents of the same type as the assigned stent
as mandated. The first 30 patients enrolled into each
rm were automatically allocated into an intravascular
ltrasound (IVUS) substudy; IVUS was performed at the
nd of the procedure according to standard protocols
fter injection of 0.2 mg of nitroglycerin with a 20- to
0-MHz ultrasound probe and with a motorized pullback
speed: 0.5 mm/s). Aspirin (100 to 300 mg/day) was
iven daily, and clopidogrel (loading dose of at least 300
g before procedure and 75 mg/day thereafter) was
dministered for at least 6 months in all patients. Serial
lood samples for creatine kinase and creatine kinase-
yocardial band were routinely obtained 8 to 12 and 16
o 24 h after the intervention.
Patients were evaluated clinically 1 and 6 months after
he procedure. Coronary angiography was planned at 6
onths (30 days) in all patients, and IVUS analysis was
lanned in the cohort of patients receiving IVUS at baseline.
ngiography was performed earlier if there were recur-
irs and a bridge element (B).ent symptoms, but if restenosis was not found during this
r
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208epeat angiography, a new angiography was done at
months.
uantitative coronary angiography and IVUS analysis. Digi-
al coronary angiograms were analyzed offline by an inde-
endent core laboratory, with a validated automated edge
etection system (Medis, Leiden, the Netherlands) (7).
atched views were selected for angiograms recorded
efore and immediately after the intervention and at
-month follow-up. Angiographic measurements were
ade both in the stent and in the stented segment (defined
s the stent plus the 5-mm edges proximal and distal to the
tent) during diastole with the contrast-filled guiding cath-
ter for magnification calibration. In case overlapping stents
ere placed, a single in-stent value was measured, and the
egment was considered as the entirely stented segment plus
he 5 mm proximal to the more proximal stent and the 5
m distal to the more distal stent implanted. Lesion RVD,
inimal luminal diameter (MLD), percent diameter steno-
is, and length were obtained at baseline. The RVD, MLD,
nd diameter stenosis were evaluated at the end of the
rocedure and at follow-up, for the in-stent, proximal edge,
istal edge, and in-segment sections. Acute gain was de-
ned as the difference between the in-stent MLD at the end
f the intervention and the MLD at baseline. Late lumen
oss was calculated as the difference in MLD between
easurements immediately after the procedure and at
ollow-up. Binary angiographic restenosis was defined as
iameter stenosis 50% by quantitative coronary angiog-
aphy (QCA), at the follow-up angiogram (8). Restenosis
atterns were assessed with the Mehran classification
ystem (9).
Quantitative IVUS analysis was performed offline by an
ndependent core laboratory, with validated software
echoPlaque, Indec Systems, Mountain View, California),
llowing semi-automated detection of luminal and stent
oundaries in reconstructed longitudinal planes. Volumetric
uantitative coronary ultrasound analysis was obtained for
essel, stent, and lumen. Neointimal volume was computed
s the difference between stent volume and lumen volume.
ercent volume obstruction was calculated as the ratio
etween the neointimal volume and stent volume  100.
ncomplete stent apposition was defined as 1 or more stent
truts clearly separated from the vessel wall with evidence of
lood speckles behind the strut in a vessel segment not
ssociated with any side branches (10).
nd points and deﬁnitions. The primary end point of the
tudy was 6-month in-stent late lumen loss (11,12). Sec-
ndary angiographic end points included in-segment late
oss, in-stent and -segment binary restenosis (50% diam-
ter stenosis), and in-stent and -segment MLD at 6 months
fter the procedure. Secondary IVUS end points were
ercent volume obstruction of the stent and incidence of late
cquired incomplete stent-to-vessel apposition at 6 months.
econdary clinical end points were 30-day and 6-month aACE rates, defined as an adjudicated composite of
ardiac death, new MI not clearly attributable to a nonin-
ervention vessel, or clinically driven target vessel revascu-
arization (TVR). In addition, clinically driven target lesion
evascularization (TLR) at 6 months after the procedure was
valuated. Death was divided into 2 categories: cardiac and
oncardiac. Cardiac death was defined as death due to acute
I or to a complication of the index procedure (including
leeding, vascular repair, transfusion reaction, or bypass
urgery) or any death in which a cardiac cause cannot be
xcluded. Noncardiac death was defined as a death not due
o cardiac causes. Myocardial infarction was defined in 2
ays: 1) Q-wave MI was diagnosed when chest pain or
ymptoms consistent with myocardial ischemia and new
athological Q waves in 2 or more contiguous electrocar-
iogram leads were present; and 2) non–Q-wave MI was
efined as creatine kinase elevated 2 times the upper
aboratory normal with the presence of elevated creatine
inase-myocardial band in the absence of new pathological
waves. Clinically driven TVR and TLR were defined as
evascularizations at the target vessel or lesion, respectively,
ssociated with positive functional ischemia study or isch-
mic symptoms and an angiographic diameter stenosis
50% by QCA or revascularization of a target vessel or
esion with diameter stenosis70% by QCA without either
ngina or a positive functional study. Stent thrombosis was
efined according to the Academic Research Consortium
riteria (13).
Additional secondary end points were device, lesion,
nd procedural success. Primary device success was de-
ned as attainment of 50% in-stent residual stenosis of
he target lesion with only the assigned device in the
bsence of device malfunction and device-related com-
lication. Lesion success was defined as attainment of
50% residual stenosis of the target lesion with the
ssigned device or any percutaneous method. Procedure
uccess was defined as attainment of a final lesion success
nd no in-hospital MACE.
An independent clinical events committee unaware of the
atients’ treatment assignment adjudicated all the clinical
vents, and an independent data safety monitoring board
lso reviewed clinical data periodically throughout the trial.
tatistical analysis. The study compared 2 experimental
tents, SymBio and Corio, with the CoStar control stent.
he comparisons of interest for the primary outcome of
n-stent late loss were SymBio versus CoStar and Corio
ersus CoStar. The sample size of 375 patients (150:150:75)
as based on the noninferiority hypothesis that the differ-
nce between late loss of SymBio or Corio and late loss of
oStar was 0.32 mm with a power of approximately 95%,
ssuming a pooled SD of 0.40 and a significance level of
.025 for each comparison. All analyses were conducted
ccording to the intention-to-treat principle. For the 2
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209rimary comparisons, a 1-sided p value of 0.025 was
onsidered significant. Analysis of variance tests and chi-
quare tests were employed, respectively, for continuous and
ategorical variables, to compare differences between the 3
tudy arms. A 2-sided p value 0.05 was considered
ignificant for all tests. Continuous data are expressed as
ean  SD, whereas dichotomous data are summarized as
requencies for all other secondary comparisons. Due to
ncomplete patient enrollment, statistical analyses were
estricted to the primary end point of in-stent late loss and
o the predefined QCA, IVUS, and clinical secondary end
oints.
esults
he study was prematurely interrupted in April 2007,
fter 246 patients had been enrolled. This decision—
ade by the study principal investigators in consultation
ith the study sponsor, Conor Medsystems, and with
oncurrence of the data safety monitoring board—followed
otification by the manufacturer of pimecrolimus, No-
artis Corporation (Basel, Switzerland), of the prelimi-
ary results from an Avantec-sponsored (Sunnyvale, Cal-
fornia) First-in-Man study evaluating the safety and
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Figure 2. Flow Diagram of the GENESIS Trial
Flow diagram of subject progress through phases of the GENESIS trial. AE  afficacy of the Avantec pimecrolimus-eluting stent. Sub- aequently, the COSTAR II trial, also using the CoStar
ES, failed to demonstrate noninferiority for the MACE
rimary end point when compared with the Taxus PES
Boston Scientific) (2). Commercial sale of the CoStar
ES was then discontinued in the markets where it was
lready available. The investigators and the sponsor
ecided to analyze the data available on all enrolled
atients at the time of trial suspension.
tudy population, procedural and in-hospital outcomes.
mong the 246 patients enrolled, 49 were randomized to
oStar, 97 to SymBio, and 100 to Corio (1 patient in the
orio Group received a Symbio stent) (Fig. 2). Baseline
linical characteristics of the patients as well as the
ngiographic and procedural characteristics of the lesions
reated are shown in Table 1. No deaths occurred during
he hospital stay. The rate of periprocedural MI was 5%
n the Corio group versus 0% in the other 2 groups. Of
he 5 periprocedural MIs, 4 were creatine kinase eleva-
ions alone without clinical sequelae, thought to be due to
he procedure and not attributed to the stent. The fifth
as an unsuccessful direct stenting, followed by pre-
ilation and successful stent placement complicated by a
istal dissection that was unsuccessfully treated with 2
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210CA and IVUS outcomes. In the Symbio group, 1 patient
as lost to follow-up. At 6 months, 7 CoStar patients
14.3%), 2 SymBio patients (2.1%), and 7 Corio patients
7%) did not receive angiographic follow-up. Angiographic
Table 1. Baseline Clinical and Procedural Characteristics of the Patients a
CoStar
(n  49)
Age (yrs) 64.4 9.6
Male sex 35 (71.4%)
Diabetes mellitus 18 (36.7%)
Insulin dependent 3/18 (16.7%)
Hypertension 36 (73.5%)
Hypercholesterolemia 36 (73.5%)
Current smoker 8 (16.3%)
Prior myocardial infarction 11 (22.5%)
Prior percutaneous intervention 13 (26.5%)
Prior bypass surgery 3 (6.1%)
Unstable angina 10 (20.4%)
Ejection fraction (%) 61.8 8.9
Glycoprotein IIb/IIIa inhibitors 1 (2%)
Target vessel
Left anterior descending 20 (40.8%)
Circumﬂex 12 (24.5%)
Right coronary artery 17 (34.7%)
ACC/AHA lesion type
A 9 (18.4%)
B1 14 (28.6%)
B2 23 (46.9%)
C 3 (6.1%)
Direct stenting 29 (59.2%)
After dilation 13 (26.5%)
Max inﬂation pressure (atm) 14.2 2.5
Number of stents/lesion 1.04 0.20
1 47 (95.9%)
2 2 (4.1%)
3 0
Stent diameter used (mm) (n  51)
2.5 10 (19.6%)
3.0 24 (47.1%)
3.5 17 (33.3%)
Stent length used (mm) (n  51)
10 9 (17.6%)
16 24 (47.1%)
22 12 (23.5%)
28 6 (11.8%)
Device success* 48 (98%)
Lesion success* 49 (100%)
Procedural success* 49 (100%)
Data are presented as n (%) or mean SD, unless otherwise specified. *Device success was not achi
the device failed or malfunctioned (n 2), or the treatment of the lesion was not completed with
achieved if the post-procedure residual stenosiswas50% (n 2). Procedure Successwas not achie
cardiac event (n 4) or both (n 1).
ACC/AHA American College of Cardiology/American Heart Association.ata are presented in Table 2. In-stent late loss was mrogressively and significantly higher with SymBio (0.96 
.73 mm) and Corio (1.40 0.67 mm) versus CoStar (0.58
0.58 mm). On average, in-stent late loss of SymBio and
f Corio was, respectively, 0.38 0.13 mm and 0.82 0.12
Lesions in the 2 Groups
SymBio
(n  97)
Corio
(n  100)
p
Value
59.9 10.1 64.1 10.0
76 (78.4%) 80 (80%)
17 (17.5%) 32 (32%)
2/17 (11.8%) 15/32 (46.9%)
65 (67%) 66 (66%)
69 (71.1%) 82 (82%)
35 (36%) 20 (20%)
29 (29.9%) 26 (26%)
28 (28.9%) 33 (33%)
0 2 (2%)
34 (35%) 25 (25%)
63.7 12.5 63.7 12.1
5 (5.2%) 6 (6%)
50 (51.5%) 49 (49%)
17 (17.8%) 24 (24%)
30 (30.7%) 27 (27%)
22 (22.7%) 30 (30%)
31 (31.9%) 31 (31%)
29 (29.9%) 35 (35%)
15 (15.5%) 4 (4%)
55 (56.7%) 53 (53%)
34 (35%) 30 (30%)
13.6 2.6 13.9 2.5
1.12 0.41 1.12 0.41
88 (90.7%) 91 (91%)
6 (6.2%) 6 (6%)
3 (3.1%) 3 (3)
(n  109) (n  112)
19 (17.4%) 25 (22.3%)
47 (43.1%) 62 (55.4%)
43 (39.5%) 25 (22.3%)
(n  109) (n  112)
17 (15.6%) 15 (13.4%)
57 (52.3%) 64 (57.2%)
25 (22.9%) 24 (21.4%)
10 (9.2%) 9 (8.0%)
95 (97.9%) 92 (92%) 0.11
97 (100%) 98 (98%) 0.68
97 (100%) 94 (94%) 0.02
hen the post-procedural residual stenosis was50% (n 1), there was a device-related AE (n 4),
igned device only (n 2) or any combination of the preceding (n 2). Lesion Success was not
sion successwas not achieved (n 1) or the patient experienced a periproceduralmajor adversend the
eved w
the ass
ved if lem higher than CoStar (p  0.001 for both). Thus, the
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211rimary end point of the study, noninferiority of SymBio or
orio in-stent late loss versus CoStar, was not met.
In-segment late loss and binary in-stent and -segment
estenosis rates were also progressively higher with SymBio
nd Corio as compared with CoStar. Among the 4 CoStar
n-segment restenoses, 3 were focal (75%) and 1 was diffuse
25%). Among the 21 SymBio restenoses, 10 were focal
48%), 7 were diffuse (33%), 3 were proliferative (14%), and
was occlusive (5%). Among the 42 Corio restenoses, 11
ere focal (26%), 19 were diffuse (46%), 9 were proliferative
Table 2. Quantitative Coronary Angiography Analysis of the Lesions Treate
CoStar
Before procedure (n  49)
Reference vessel diameter (mm) 2.81 0.47
Minimal luminal diameter (mm) 0.72 0.31
Diameter stenosis (%) 74 11
Lesion length (mm) 14.4 6
After procedure (n  49)
In-segment
Minimal luminal diameter (mm) 2.41 0.49
Diameter stenosis (%) 16 7
Acute gain (mm) 1.69 0.52
Proximal edge
Minimal luminal diameter (mm) 2.76 0.53
Diameter stenosis (%) 12 8
In-stent
Minimal luminal diameter (mm) 2.82 0.42
Diameter stenosis (%) 5 6
Acute gain (mm) 2.10 0.49
Distal edge
Minimal luminal diameter (mm) 2.53 0.57
Diameter stenosis (%) 10 7
Follow-up (n  42)
In-segment
Minimal luminal diameter (mm) 2.01 0.61
Diameter stenosis (%) 29 16
Proximal edge
Minimal luminal diameter (mm) 2.59 0.56
Diameter stenosis (%) 11 12
In-stent
Minimal luminal diameter (mm) 2.27 0.64
Diameter stenosis (%) 19 19
Distal edge
Minimal luminal diameter (mm) 2.34 0.60
Diameter stenosis (%) 13 10
Late loss (mm)
In-segment 0.42 0.48
In-stent 0.58 0.58
Binary angiographic restenosis
In-stent 3 (7.1%)
In-segment 4 (9.5%)
Data are presented as mean SD or n (%).21%), and 3 were occlusive (7%). tThe IVUS results, presented in Table 3 and representing
subset of enrolled patients, substantially confirm the QCA
ata of the complete cohort.
0-day and 6-month clinical outcomes. Clinical events are
resented in Table 4. Between the end of the hospital
tay and the first month after treatment, 1 additional MI,
aused by early stent thrombosis and treated with percuta-
eous revascularization, was recorded in the Corio group.
t 6 months, no cardiac deaths occurred, whereas 1 MI in
he SymBio group (caused by late stent thrombosis, and
e 3 Groups
SymBio Corio p Value
(n  97) (n  100)
2.87 0.50 2.79 0.45
0.78 0.37 0.76 0.38
72 13 73 12
13.8 5.4 14.9 5.5
(n  97) (n  100)
2.41 0.45 2.33 0.47
17 8 18 12
1.63 0.46 1.57 0.50
2.83 0.50 2.82 0.52
12 9 11 8
2.83 0.39 2.81 0.38
7 6 6 5
2.05 0.46 2.04 0.43
2.54 0.53 2.47 0.50
11 9 12 7
(n  95) (n  93)
1.71 0.68 1.30 0.68 0.001
40 21 54 22
2.51 0.71 2.39 0.74
14 18 15 21
1.89 0.81 1.41 0.75 0.001
33 25 47 25
2.29 0.61 2.03 0.75
13 16 19 23
0.69 0.58 1.07 0.59 0.001
0.96 0.73 1.40 0.67 0.001
19 (20%) 38 (40.9%) 0.001
21 (22.1%) 42 (45.2%) 0.001d in threated with percutaneous revascularization) and 2 addi-
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212ional MIs in the Corio group (both periprocedural during
VR) were recorded. According to the angiographic results,
lso the rates of TLR and TVR were progressively reduced
y CoStar versus SymBio versus Corio, as was the cumula-
ive MACE rate.
iscussion
iven the negative outcome of the CoStar II trial in which
he CoStar paclitaxel-eluting stent was shown to be inferior
o the Taxus-Liberte stent, one might question whether
ailure of the Conor reservoir technology is an explanation
or the results in this trial. The data in this trial do not
Table 3. Intravascular Ultrasound Analysis of the Lesions Treated in the 3
CoStar
After procedure (n  29 analyzed  14)
Target segment length (mm) 20.1 4.8
Vessel volume (mm3) 252.1 109.4
Stent volume (mm3) 126.8 42.9
Lumen volume (mm3) 125.6 41.9
Incomplete stent apposition 4/24 (16.7%)
Follow-up (n  29 analyzed  16)
Target segment length (mm) 20.8 5.4
Vessel volume (mm3) 319.3 144.7
Stent volume (mm3) 149.6 66.5
Lumen volume (mm3) 122.0 50.5
Neointimal volume (mm3) 27.6 26.6
Percent volume obstruction (%) 16.6 12
Incomplete stent apposition 3/20 (15%)
Late acquired 0
Persistent 3/20 (15.0%)
Data are presented as mean SD or n (%).
Table 4. 30-Day and 6-Month Clinical Events in the 3 Groups
CoStar
(n  49)
SymBio
(n  97)
Corio
(n  100)
p
Value
30-day
Death 0 0 0
Myocardial infarction 0 0 6 (6%)
Target vessel revascularization 0 0 1 (1%)
Major adverse cardiac events 0 0 6 (6%) 0.02
Stent thrombosis 0 0 1 (1%)
6-month
Death 1 (2%) 0 0
Cardiac death 0 0 0
Myocardial infarction 0 1 (1%) 8 (8%)
Target lesion revascularization 1 (2%) 14 (14.4%) 32 (32%) 0.001
Target vessel revascularization 1 (2%) 14 (14.4%) 35 (35%)
Major adverse cardiac events 1 (2%) 14 (14.4%) 39 (39%) 0.001
Stent thrombosis 0 1 (1%) 1 (1%)tData are presented as n (%).upport this explanation, because the angiographic and
linical outcomes in the CoStar arm in this study are similar
o those reported in the trials that led to CE Mark approval
nd are markedly better than historical data on bare metal
tent outcomes in a similar cohort of patients. In fact,
utcomes on the CoStar II trial were attributed to elution of
aclitaxel, a drug with a narrow therapeutic index, at the
ower end of the release kinetic specification in the CoStar
tents used in this trial versus previous trials that, although
ithin allowable specifications, were inadequate for the
ore complex 2-vessel disease patients studied in that trial.
his conclusion was supported by a post hoc analysis
emonstrating that noninferiority was met in patients with
nly single lesions in this trial (14). Additional evidence that
he reservoir technology successfully delivered drug is the
bservation of clinical outcomes in the pimecrolimus arm
hat were worse than expected compared with historical bare
etal stent data. Thus, there seem to be 3 main findings of
his study comparing different drugs as eluted from the
onor reservoir-based stent: 1) pimecrolimus is not effective
s an antirestenotic agent; 2) paclitaxel demonstrates activity
s an antirestenotic agent; and 3) dual drug delivery with
ndependent release kinetic and profile, using the Conor
eservoir-based stent, is feasible.
The unexpected outcome of this study was that the
ENESIS trial failed to show a significant angiographic or
linical benefit of pimecrolimus. Although underpowered
nd not designed to assess clinical end points, the GENESIS
rial outcomes suggest that in humans the drug might
xacerbate the restenotic response, thus leading to results
orse than those observed with bare metal stents. Indeed in
Subgroups
SymBio Corio p Value
 36 analyzed  24) (n  32 analyzed  17)
21.3 8.7 20.4 9.3
281.6 93.9 320.4 139.1
145.5 57.6 150.7 77.8
144.7 57.6 149.9 77.5
8/27 (29.6%) 6/26 (23.1%)
 36 analyzed  26) (n  32 analyzed  16)
21.0 8.3 22.1 9.3
293.6 100.8 330.3 150.3
139.5 55.6 161.4 85.4
100 39.9 98.8 62.3
39.5 24.7 62.6 29.4
27.1 12.4 41.2 11.5 0.001
5/28 (17.8%) 2/20 (10%) 0.91
0 0
5/28 (17.8%) 2/20 (10.0%)IVUS
(n
(nhe GENESIS trial, stents eluting only pimecrolimus
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213howed the worst late loss, which compares unfavorably
ith the late loss reported in published reports for bare-
etal stents in similar lesions and patients.
Pimecrolimus has been approved as topical treatment for
nflammatory dermatologic diseases. Despite its “limus” name,
t is not a rapamycin analogue. It is best classified as a
acrolimus analogue that exerts multiple anti-inflammatory
ffects, including inhibition of interleukin-2 synthesis via
alcineurin inhibition and inhibition of interleukin-4,
nterferon-, and the release of inflammatory cytokines
rom mast cells. In contrast to other “limus” drugs, such as
irolimus, it does not bind to the mammalian target of
apamycin. Thus, it does not specifically exert anti-
roliferative actions, having no direct effect on cell cycle
egulation. However, it has been assumed that it might do
o indirectly by interleukin-2 inhibition. Several animal
tudies strongly suggested that it would be clinically effective
n humans as an antirestenotic molecule when applied
ocally to atherosclerotic plaques treated with stent implan-
ation (15,16).
However, the suggestions of clinical efficacy from the
nimal data were not confirmed by this current human
tudy. The reasons for this failure are currently unknown.
owever, several explanations can be hypothesized. First,
iscrepancies in results between animal experiments and
uman trials are well known. The porcine model for the
athologic reaction to stent implantation is best-suited for
etermination of safety. Relative human efficacy is less
redictable in this model and can only be definitely ascer-
ained in clinical trials (17). Moreover, it is possible that,
hereas inflammation can play an important role in neoin-
imal proliferation in porcine stent models, the inflamma-
ory response to stent implantation as affected by this drug
ight play a minor if not insignificant role as a determinant
f the restenotic process in humans. Because pimecrolimus
as no antiproliferative properties but mainly antiinflamma-
ory and immunosuppressant actions, its lack of efficacy
ould tend to undermine the role of inflammation as central
n the restenotic process in humans. Indeed, other drug-
luting stents aimed at inhibiting the inflammatory and
mmune reaction to stent implantation, such as stents
luting dexamethasone, failed to show benefits when com-
ared with traditional bare-metal stents (18–20).
Despite market withdrawal, the CoStar PES provided
ncouraging results in this study, confirming the positive
utcomes of previous trials, where this stent showed the
owest late loss among currently available PES (21,22) and
uperiority to the respective bare-metal stent (1). The
utcomes of patients treated with CoStar in the GENESIS
rial are similar to those reported in the COSTAR II trial,
here examination of the outcomes suggested that the
elease of paclitaxel—a drug with a narrow therapeutic
ndex—was insufficient for the more complex lesions and
atients enrolled in the COSTAR II study (14). FThe CoStar PES differs from other available drug-eluting
tents, because it has the drug—mixed with a bioresorbable
olymer—loaded in reservoirs cut into the stent rather than
aving the drug and the polymer on the surface of the stent.
his property reduces the exposure of the vessel wall to the
olymer and results in an inert bare-metal stent, after the
lution of the drug and the dissolution of the polymer.
oreover, these technological advancements of the Conor
tent platform—with its laser cut reservoirs and its
ioresorbable polymer, which also allow controlled release
f drugs—open the road to further investigations with
ifferent drugs loaded in the reservoirs and with specific
elease patterns, tailored to the different mechanisms in-
olved in the pathophysiologic reaction to stent implanta-
ion. The GENESIS trial is the first trial to use the Conor
eservoir technology to enable dual drug delivery for the
reatment of coronary lesions. This trial has indeed demon-
trated the ability to deliver 2 drugs independently, with
ach drug having a different effect on the tissue response to
oronary intervention. The theoretical advantages of the
elivery of more than 1 drug include the ability to release
ultiple agents that synergistically work on different mech-
nistic pathways to inhibit neointimal growth or produce
ther biologic effects. Other drugs of interest also include
ntithrombotic agents or pharmacological therapies that can
nhibit reperfusion injury during acute MI.
tudy limitations. The major limitation of this study was
he early termination of enrollment. Thus, the study is
nderpowered for its primary angiographic end point. All
nalyses are post-hoc in nature: descriptive statistics only are
resented for the primary and secondary end points, and no
tatistical analysis on differences in clinical end points
which the trial was not originally powered for) can be
ade. Moreover, the external validity of the trial is limited
y the specific inclusion and exclusion criteria, thus limiting
he applicability of the findings to the enrolled cohort of
atients with selected lesions.
onclusions
n native coronary artery lesions, stents eluting pimecroli-
us or the dual combination of pimecrolimus and paclitaxel
ailed to show angiographic noninferiority when compared
ith paclitaxel-eluting stents.
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